Omega Therapeutics Inc (OMGA)
2.08
-0.16
(-7.14%)
USD |
NASDAQ |
Jun 28, 16:00
2.01
-0.07
(-3.37%)
After-Hours: 20:00
Omega Therapeutics Research and Development Expense (Annual): 77.17M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 77.17M |
| December 31, 2022 | 81.17M |
| December 31, 2021 | 47.86M |
| Date | Value |
|---|---|
| December 31, 2020 | 21.06M |
| December 31, 2019 | 11.93M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
11.93M
Minimum
2019
81.17M
Maximum
2022
47.84M
Average
47.86M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Altimmune Inc | 65.80M |
| Macrogenics Inc | 166.58M |
| Viking Therapeutics Inc | 63.81M |
| vTv Therapeutics Inc | 13.60M |
| Rhythm Pharmaceuticals Inc | 134.95M |